Grace Therapeutics, Inc.

Analysis for Ticker: GRCE

Grace Therapeutics Inc is a bio-pharmaceutical company that uses nanoparticle technology to improve existing medications for the treatment of rare and orphan diseases. The internal math reveals a corporate machine engineered for the extraction of capital rather than the advancement of medicine. Since its inception, the company has burned through an accumulated deficit exceeding 224$ million while generating exactly 0$ in product revenue. Despite these massive losses, the entire operation is run by a staff of only six employees. This is like a lemonade stand that spends 224$ million on fancy cups, high-priced lawyers, and executive bonuses but has never actually sold a single cup of lemonade. The core business is the systematic transfer of investor wealth into the pockets of a small group of insiders through highly complex legal contracts.